The United Kingdom and the United States have announced a key trade agreement that will guarantee no import taxes on UK pharmaceutical exports being sold in the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has committed to increase funding on drugs through the NHS. This pledge secures that tariffs on these vital exports will stay at nothing for a period of the next three years.
This development follows previous threats to hike tariffs on branded drug products, with potential rates discussed up to 100%.
"This agreement between the Britain reinforces the international landscape for innovative medicines and introduces much-needed fairness to American-British drug exports," a release said.
Economic Importance
Drugs represent one of the the United Kingdom's largest goods shipped to the US, which is clearly the biggest buyer for leading British pharmaceutical firms.
Statistics reveal that in the 12 months to the end of last September, the UK sold drugs worth billions to the US. This value accounted for 17.4% of British export trade in that span.
"This guarantee secures work, increases investment and paves the way for the UK to become a worldwide center for medical research," a minister stated.
Specific UK Commitments
The agreement involves several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a goal to double total NHS spending on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The amount manufacturers must return to the NHS to control costs will be restricted at fifteen percent. In the past, refunds exceeded 20%.
Industry Background
The pact follows a long-running dispute between the sector and the British authorities over drug pricing and regulatory access.
The disagreement were intensified by assertions that US customers were charged several times more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been paused or cancelled, while multi-billion-dollar expansions have been directed toward US facilities.
One official stated that the NHS must spend more on drugs, noting that its expenditure on drugs had declined as a proportion of its total funding over the past decade.
